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INTRODUCTION
Epithelial ovarian cancer is the leading cause of disease-related 
deaths from gynecologic malignancies, and its incidence and 
mortality rates in Korea are increasing.1,2 In addition to well-known 
prognostic factors, such as stage, histology, grade, and residual 
disease after surgery,3 clinical studies are underway to identify 
potentially actionable mutations in ovarian cancer through a 
greater understanding of molecular mechanisms and to eval-
uate therapeutic agents of these mutations.4,5
Next generation sequencing (NGS) is able to reveal genom-
ic aberrations by harnessing its massively parallel sequencing 
capability to analyze multiple genes simultaneously in a single 
assay. Moreover, this technology has recently become more af-
fordable, leading to large collaborative studies on whole ge-
nomes that have been able to document targetable genes and 
predictive biomarkers in cancer.6,7 As of March 2017, the Nation-
al Health Insurance system in Korea has paid the cost of NGS 
panels for several types of solid tumors, including ovarian can-
cer, and the number of NGS tests has increased exponentially.
We reviewed retrospective data of 84 patients who under-
Integrating a Next Generation Sequencing Panel  
into Clinical Practice in Ovarian Cancer
Yong Jae Lee1, Dachan Kim1, Hyun-Soo Kim2, Kiyong Na2, Jung-Yun Lee1,  
Eun Ji Nam1, Sang Wun Kim1, Sunghoon Kim1, and Young Tae Kim1
1Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul; 
2Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Purpose: Few efforts have been made to integrate a next generation sequencing (NGS) panel into standard clinical treatment of 
ovarian cancer. The aim of this study was to investigate the clinical utility of NGS and to identify clinically impactful information 
beyond targetable alterations.
Materials and Methods: We conducted a retrospective review of 84 patients with ovarian cancer who underwent NGS between 
March 1, 2017, and July 31, 2018, at the Yonsei Cancer Hospital. We extracted DNA from formalin-fixed, paraffin-embedded tis-
sue samples of ovarian cancer. The TruSight Tumor 170 gene panel was used to prepare libraries, and the MiSeq instrument was 
used for NGS.
Results: Of the 84 patients, 55 (65.1%) had high-grade serous carcinomas. Seventy-three (86.7%) patients underwent NGS at the time 
of diagnosis, and 11 (13.3%) underwent NGS upon relapse. The most common genetic alterations were in TP53 (64%), PIK3CA (15%), 
and BRCA1/2 (13%), arising as single nucleotide variants and indels. MYC amplification (27%) was the most common copy num-
ber variation and fusion. Fifty-seven (67.9%) patients had more than one actionable alteration other than TP53. Seven (8.3%) cases 
received matched-target therapy based on the following sequencing results: BRCA1 or 2 mutation, poly ADP ribose polymerase 
inhibitor (n=5); PIK3CA mutation, AKT inhibitor (n=1); and MLH1 mutation, PD-1 inhibitor (n=1). Fifty-three (63.0%) patients had 
a possibility of treatment change, and 8 (9.5%) patients received genetic counseling. 
Conclusion: Implementation of NGS may help in identifying patients who might benefit from targeted treatment therapies and 
genetic counseling.  
Key Words:  Next generation sequencing, ovarian cancer, targetable alterations
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: April 10, 2019   Revised: July 30, 2019
Accepted: July 31, 2019
Corresponding author: Jung-Yun Lee, MD, PhD, Department of Obstetrics and 
Gynecology, Institute of Women’s Life Medical Science, Yonsei University College 
of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-2230, Fax: 82-2-313-8357, E-mail: jungyunlee@yuhs.ac
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2019
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2019 Oct;60(10):914-923
https://doi.org/10.3349/ymj.2019.60.10.914
915
Yong Jae Lee, et al.
https://doi.org/10.3349/ymj.2019.60.10.914
went NGS and reported our experiences with integrating an 
NGS panel into clinical practice in ovarian cancer. We identified 
potentially actionable genomic alterations and used them to 
evaluate the therapeutic utility of individual treatment options.
 
MATERIALS AND METHODS
Patient samples
Between March 1, 2017 and July 31, 2018, 84 tumor samples 
from ovarian cancer patients treated at Yonsei Cancer Center 
were subjected to NGS. The tumor samples were prepared 
from formalin-fixed, paraffin-embedded (FFPE) tissues. An 
expert pathologist (H.S.K.) reviewed hematoxylin and eosin-
stained slides to ensure that ≥20% of the nucleated cells in the 
sample were derived from the tumor. Tumor specimens were 
macrodissected after a hematoxylin-eosin reference slide check 
to ensure the proportion of tumor content. For DNA and RNA 
extraction, two to five slides of resected specimens of a thick-
ness of 5 μm were needed. A board-certified gynecological pa-
thologist diagnosed all cases. We performed a retrospective re-
view of patient medical records, including age, histologic type, 
stage as defined by the International Federation of Gynecology 
and Obstetrics, and the timing of the NGS test.
NGS
We performed NGS analysis of 84 FFPE cancers with sufficient-
ly high tumor cellularity (>30%). Genomic DNA was extracted 
using a Maxwell CSC DNA FFPE Kit (Promega, Madison, WI, 
USA), according to the manufacturer’s instructions. The prod-
ucts were sequenced on a MiSeq System (Illumina, San Diego, 
CA, USA). Mutational and copy number analyses were per-
formed using a TruSight Tumor 170 panel (Illumina) that cov-
ers, respectively, 170 genes and 59 genes for mutational and 
copy number analyses (Supplementary Table 1, only online). 
For mutational analysis, FASTQ files were uploaded on the Il-
lumina BaseSpace software (Illumina) for variant interpreta-
tion. Only variants in coding regions and promoter regions or 
splice variants were retained. In addition, we retained only vari-
ants present in <1% of the population, according to ExAC and 
1000 genomes, and also present in >5% of reads with a mini-
mum read depth of 250. All retained variants were reviewed 
against reference websites [Catalogue of Somatic Mutations in 
Cancer (http://evs.gs.washington.edu/EVS/), Precision On-
cology Knowledge Base (http://oncokb.org), and dbSNP 
(https://www.ncbi.nlm.nih.gov/snp)]. Only pathogenic vari-
ants were selected. In copy number analysis, only genes with 
a more than two-fold change relative to the average level were 
considered for amplification. We also performed total nucleic 
acid extraction to obtain ribonucleic acid (RNA). An Archer 
FusionPlex Solid Tumor Kit (ArcherDx, Boulder, CO, USA) 
was used to analyze the RNA for fusions and splice variants: 
the kit covers 55 genes.8 Specimens yielded more than 40 ng 
of DNA and RNA. DNA fragment sizes of at least 79 bp and 
RNA fragment sizes of at least 63 bp were selected for targeted 
sequencing. Our goal in this study was to assess the feasibility 
and utility of using the Illumina MiSeq platform to integrate a 
NGS panel into a real-world setting of ovarian cancer clinical 
practice.
 
Data interpretation 
Actionable somatic alterations are defined as those that could 
be targeted by a drug available for on-label, off-label, or in clini-
cal trials. These alterations were selected based on a literature 
search of the MD Anderson Knowledge Base for Precision Med-
icine (http://PCT.MDAnderson.org), The Cancer Genome At-
las (TCGA) (http://cancergenome.nih.gov/), and genes related 
to homologous recombination repair (HRR) (Supplementary 
Table 2, only online).  
We used the following guidelines to classify these alterations 
into four tiers.9 Tier 1 comprised known tumor type-specific 
actionable somatic mutations of confirmed clinical utility in 
predicting responses to U.S. Food and Drug Administration 
(FDA)-approved therapies, prognoses, diagnoses, or increased 
risk of inherited cancer. Tier 2 included actionable somatic mu-
tations in other tumor types or somatic mutations in targetable 
pathways with potential clinical significance, such as suscep-
tibility to FDA-approved therapies, prognoses, diagnoses, or 
increased risk of inherited cancer. Alterations of unknown 
clinical significance were classified as Tier 3, and those con-
sidered benign or likely so were grouped in Tier 4.
Clinical implications
We defined the term clinical implication as the capability of 
NGS results to provide useful information about patients and 
their family members that could be used to diagnose, moni-
tor, predict the occurrence of disease and to create informed 
choices about treatment options.10 These clinical implications 
were categorized into three categories to evaluate the clinical 
impact of NGS results: 1) those who received targeted therapy; 
2) identification of potential candidates for targeted therapy; 
and 3) genetic counseling for the patient and other at-risk fam-
ily members. 
Ethical statement 
This study was approved by the Institutional Review Board of 
Severance Hospital at Yonsei University College of Medicine 
(IRB No. 4-2018-0518).
RESULTS
Patient clinicopathologic characteristics
A total of 227 ovarian cancer patients were treated in our insti-
tution between March 1, 2017 and July 31, 2018, and 84 (37%) 
patients underwent NGS analysis. Table 1 illustrates the base-
916
Clinical Utility of Next Generation Sequencing
https://doi.org/10.3349/ymj.2019.60.10.914
line clinicopathological characteristics of the 84 patients who 
underwent NGS. The median age of this group was 54 years 
(range, 34–77). The most common histologic type was high-
grade serous carcinoma (65.1%). Sixty-eight (80.7%) patients 
had advanced-stage disease (Stages III/IV). Forty-nine (57.8%) 
patients underwent primary debulking surgery (PDS), and 35 
(42.2%) underwent neoadjuvant chemotherapy (NAC). Thirty-
nine (45.8%) patients underwent NGS during PDS: 8 (9.6%) dur-
ing pre-NAC, 26 (31.3%) during interval debulking surgery (IDS), 
and 11 (13.3%) patients at the time of relapse.
Genomic alterations 
All patients had at least one genomic alteration. The mean num-
ber of mutations per patient was 10.5. Fifty-seven (67.9%) pa-
tients had more than one actionable alteration other than TP53. 
Of the 57 patients, 16 (28.6%) had a mutation in HRR-related 
genes (Fig. 1). In addition, we analyzed the distribution of pa-
tients with somatic BRCA mutations at each time point of NGS 
analysis. Of the 11 patients with somatic BRCA mutations, there 
were 2 patients (2/8, 25.0%) in the Pre-NAC group, 5 patients 
(6/39, 15.4%) in the PDS group, 2 patients (2/26, 7.7%) in the IDS 
group, and 2 patients (1/11, 9.1%) in the relapse group. The 
chemo-naive group (pre-NAC, PDS) and the chemotherapy 
group (IDS, relapse) comprised 8/47 (17.0%) and 3/37 (8.1%), 
respectively. We also reviewed the Germline BRCA status for 
the patients (Supplementary Table 3, only online). Of the 84 pa-
tients, 12 (14.3%) had germline BRCA1/2 mutation, 50 (59.5%) 
had no germline BRCA1/2 mutation, and 26 (31.0%) did not un-
dergo the germline BRCA test. Table 2 shows the tumor molec-
ular profiles and clinical utility of actionable somatic mutations. 
Among single nucleotide variants and indel in tiers 1 or 2, the 
most frequently identified mutations were in TP53 (64%), 
PIK3CA (15%), and BRCA1/2 (17%) (Fig. 2A). Among copy num-
ber variations and fusions, the most frequently identified mu-
tations were in MYC (27%), TFRC (24%), and CCNE1 (13%) (Fig. 
2B). The most commonly mutated genes among the HRR-re-
lated genes in tiers 1 or 2 included BRCA1 (11%), BRCA2 (9%), 
ATM (4%), and CHEK1 (4%) (Fig. 2C). The most frequently mu-
tated genes among the TCGA druggable genes in tiers 1 and 2 
were KRAS (16%), CCNE1 (13%), ERBB2 (5%), RICTOR (1%), and 
ERBB3 (1%) (Fig. 2C). Identified mutations were categorized 
into six pathways or functional groups: cell cycle (RB1, CCNE1, 
CDK2, CCND1, CDK4, CDK6, CDKN2A, MYC, SRC, JAK1, JAK2, 
STAT1, STAT3), DNA damage response (CHEK1, CHEK2, BRCA1, 
BRCA2, MLH1, MSH2, ATM, ATR), p53 (CDKN2A, MDM2, 
MDM4, TP53), PI3K-AKT-mTOR signaling (PI3KCA, PIK3RA, 
PTEN, AKT1, AKT2, MTOR, RICTOR, TSC1, TSC2), Ras-Raf, 
MEK-Erk/JNK signaling (KRAS, HRAS, BRAF, RAF1, MAP2K1, 
MAP2K2, MAP2K4, MAPK1, MAPK3), and the RTK signaling 
family (EGFR, ERBB2, ERBB3, ERBB4, PDGFRA, PDGFRB, KIT, 
FGFR1, KDR). We analyzed the numbers of mutations with six 
functional and targetable pathways (Fig. 2D). The most fre-
quently identified mutations were MYC in the cell cycle path-
way, BRCA1 in the DNA damage response pathway, TP53 in 
the p53 pathway, PIK3CA in the PI3K-AKT-mTOR pathway, 
KRAS in the Ras-Raf-MEK-Erk/JNK pathway, and FGFR1 in 
the RTK signaling pathway.   
Targeted therapies 
Of 57 patients with more than one actionable alteration, 7 (8.3%) 
were treated with matched therapies; 49 underwent standard 
chemotherapy without matched therapy; and 1 patient was 
treated with immunohistochemistry matched therapy (Fig. 3). 
Among the patients treated with matched therapies, five were 
Table 1. Clinicopathological Characteristics (n=84)
Characteristic Values
Age (yr) [median (range)] 54 (34–77)
Histologic type
High grade serous 55 (65.1)
Low grade serous 4 (4.8)
Clear 10 (12.0)
Endometrioid 6 (7.3)
Mucinous 2 (2.4)
Other 7 (8.4)
FIGO stage
I 12 (14.5)
II 4 (4.8)
III 33 (39.8)
IV 35 (40.9)
Treatment type
PDS 49 (57.8)
NAC 35 (42.2)
Tissue tested
PDS 39 (45.8)
Pre-NAC 8 (9.6)
IDS 26 (31.3)
Relapse 11 (13.3)
FIGO, International Federation of Gynecology and Obstetrics; PDS, primary 
debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking 
surgery.
Values are presented as n (%) or median (range) unless otherwise indicated.
Fig. 1. Pie chart of the distribution of actionable somatic alterations. HRR, 
homologous recombination repair.
27
(32.1%)
57
(67.9%) 41
(71.4%)
16
(28.6%)
Actionable alteration except TP53 (≥1)
No actionable alteration
HRR gene
Others
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Table 2. Tumor Molecular Profiles and Clinical Utility of Targetable Somatic Mutations
Patient Cell type Alterations
Clinical implication
Actual change Potential change Genetic counseling
1 High grade serous BRCA1_c.1961delA, 
  BRCA2_c.1806delA
No Consider future PARP inhibitor,  
  consider future PARP inhibitor
Yes 
2 High grade serous BRCA1_c.1961delA, 
  BRCA2_c.1806delA
No Consider future PARP inhibitor,  
  consider future PARP inhibitor
No 
3 High grade serous BRCA1_c.3548A>G No Consider future PARP inhibitor No
4 High grade serous BRCA2_c.3896A>T No Consider future PARP inhibitor No
5 Mucinous ERBB2_Amplification No Consider future ERBB inhibitor No
6 Seromucinous BRCA2_c.2795_2796delAC 
  KRAS_C.38G>A
No Consider future PARP inhibitor,  
  consider future MAPK inhibitor
No
7 Clear cell PTEN_G850A No Consider future PTEN inhibitor No
8 Endometrioid PIK3CA_241G>A 
  PTEN_19G>T
No Consider future AKT inhibitor,  
  consider future PTEN inhibitor
No
9 High grade serous BRAF_Amplification No Consider future BRAF inhibitor No
10 High grade serous BRCA2_c.1805_1806insA 
  KRAS_Amplification
No Consider future PARP inhibitor,  
  consider future MAPK inhibitor
No
11 Low grade serous KRAS_c.G38A 
  MLH1_c440_44insT
Enrolled in NCT02628067  
  (pembrolizumab)
Consider future MAPK inhibitor Yes
12 High grade serous ATM_Amplification 
  CCNE1_Amplification
No Consider future PARP inhibitor,  
  consider future CDK inhibitor
No
13 High grade serous BRCA2_c.1399A>T Treated with Olaparib No Yes
14 High grade serous MET_Amplification 
  PIK3CA_Amplification
No Consider future MET inhibitor,  
  consider future AKT inhibitor
No
15 High grade serous CCNE1_Amplification No Consider future CDK inhibitor No
16 High grade serous CCNE1_Amplification 
  PIK3CA_Amplification
No Consider future CDK inhibitor,  
  consider future AKT inhibitor
No
17 Mixed  
  (clear+endometrioid)
CCNE1_Amplification No Consider future CDK inhibitor No
18 High grade serous CCNE1_Amplification 
  KRAS_Amplification 
  PIK3CA_Amplification
No Consider future CDK inhibitor,  
   consider future MAPK inhibitor, 
consider future AKT inhibitor
No
19 High grade serous KRAS_c.35G>T 
  NRAS_Amplification
No Consider future MAPK inhibitor, 
  consider future MAPK inhibitor
No
20 High grade serous CDK4_Amplification 
  PIK3CA_Amplification
No Consider future CDK4 inhibitor,  
  consider future AKT inhibitor
No
21 High grade serous PIK3CA_Amplification No Consider future AKT inhibitor No
22 Carcinosarcoma FGFR1_Amplification 
  KIT_Amplification
No Consider future FGFR inhibitor,  
  consider future KIT inhibitor
No
23 High grade serous BRCA1_c.3991C>T No Consider future PARP inhibitor Yes
24 High grade serous BRCA2_c.2798del_2799delCA Treated with Olaparib No Yes
25 High grade serous PIK3CA_c.1035T>A 
  ERBB2_Amplification
No Consider future AKT inhibitor, 
  consider future ERBB inhibitor
No
26 High grade serous BRCA2_c.2808_2811del No Consider future PARP inhibitor Yes
27 Clear cell PIK3CA_c.3140A>T No Consider future AKT inhibitor No
28 High grade serous RICTOR_Amplification No Consider future RICTOR inhibitor No
29 Mucinous BRAF_c.1799T>A 
  PIK3CA_c.1357G>A
No Consider future BRAF inhibitor, 
  consider future AKT inhibitor
No
30 Clear cell PIK3CA_c.3140A>G 
  FGFR1_Amplification
No Consider future AKT inhibitor,  
  consider future FGFR inhibitor
No
31 Clear cell PIK3CA_c.3140A>G No Consider future AKT inhibitor No
32 High grade serous PTEN_c.604dupA 
   BRAF_Amplification 
CCNE1_Amplification 
KRAS_Amplification
No Consider future PTEN inhibitor,  
   consider future BRAF inhibitor,  
consider future CDK inhibitor,  
consider future MAPK inhibitor
No
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Table 2. Tumor Molecular Profiles and Clinical Utility of Targetable Somatic Mutations (continued)
Patient Cell type Alterations
Clinical implication
Actual change Potential change Genetic counseling
33 High grade serous CCNE1_Amplification 
   EGFR_Amplification 
FGFR1_Amplification 
KRAS_Amplification 
PIK3CA_Amplification
No Consider future CDK inhibitor, 
   consider future EGFR inhibitor, 
consider future FGFR inhibitor,  
consider future MAPK inhibitor,  
consider future AKT inhibitor
No
34 Seromucinous PIK3CA_c.1624G>A 
  KRAS_c.35G>T
No Consider future AKT inhibitor,  
  consider future MAPK inhibitor
No
35 Carcinosarcoma KRAS_c.35G>T No Consider future MAPK inhibitor No
36 High grade serous BRCA1_c.5093_5096del Treated with Olaparib No No
37 High grade serous BRAF_Amplification 
  ERBB2_Amplification
No Consider future BRAF inhibitor,  
  consider future ERBB inhibitor. 
No
38 High grade serous ATM_Amplification 
   CCNE1_Amplification 
FGFR1_Amplification 
PIK3CA_Amplification
No Consider future PARP inhibitor,  
   consider future CDK inhibitor,  
consider future FGFR inhibitor,  
consider future AKT inhibitor
No
39 High grade serous BRAF_Amplification 
   FGFR2_Amplification 
MET_Amplification
No Consider future BRAF inhibitor,  
   consider future FGFR inhibitor,  
consider future MET inhibitor
No
40 Endometrioid PIK3CA_c.113G>A 
  PTEN_c.540C>G
No Consider future AKT inhibitor,  
  consider future PTEN inhibitor
No
41 High grade serous KRAS_c.35G>T 
  ERBB3_Amplification
No Consider future MAPK inhibitor, 
  consider future ERBB inhibitor
No
42 Clear cell ERBB2_Amplification No Consider future ERBB inhibitor No
43 Clear cell PIK3CA_c.3140A>G 
  FGFR1_Amplification
No Consider future AKT inhibitor,  
  consider future FGFR inhibitor
No
44 High grade serous CCNE1_Amplification No Consider future CDK inhibitor No
45 High grade serous ATM_Amplification 
  CHEK1_Amplification
No Consider future PARP inhibitor,  
  consider future CHEK1 inhibitor
No
46 High grade serous BRCA2_c.6952C>T 
  PIK3CA_Amplification
Treated with Olaparib
Consider future AKT inhibitor
Yes
47 Endometrioid PIK3CA_Amplification Treated with Olaparib based  
  on germline BRCA mutation
Consider future AKT inhibitor Yes
48 Seromucionous KRAS_c.35G>T  
  PIK3CA_c.1810T>C
No Consider future MAPK inhibitor,  
  consider future AKT inhibitor
No
49 Clear cell PTEN_c.810G>T No Consider future PTEN inhibitor No
50 Endometrioid PIK3CA_c.1624G>A 
   CCNE1_Amplification 
CHEK1_Amplification 
FGFR2_Amplification 
KIT_Amplification 
MDM2_Amplification 
PIK3CA_Amplification
No Consider future AKT inhibitor,  
   consider future CDK inhibitor,  
consider future PARP inhibitor,  
consider future FGFR inhibitor,  
consider future KIT inhibitor,  
consider future MDM2 inhibitor, 
consider future AKT inhibitor
No
51 Low grade serous KRAS_c.35G>A 
  BRAF_Amplification
No Consider future MAPK inhibitor, 
  consider future BRAF inhibitor
No
52 High grade serous KRAS_c.38G>A 
  CCNE1_Amplification
No Consider future MAPK inhibitor,  
  consider future CDK inhibitor
No
53 High grade serous BRCA1_c.1399A>T No Consider future PARP inhibitor No
54 High grade serous BRAF_Amplification 
   CCNE1_Amplification 
PTEN_Amplification
No Consider future BRAF inhibitor, 
   consider future CDK inhibitor,  
consider future PTEN inhibitor
No
55 High grade serous KRAS_Amplification No Consider future MAPK inhibitor No
56 Clear cell PIK3CA_c.1624G>A No Consider future ATK inhibitor No
57 High grade serous PIK3CA_c.1633G>A Enrolled in NCT03017521
  (ATK inhibitor)
No No
PARP, poly ADP ribose polymerase.
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Fig. 2. Mutation, copy number variation profiling. (A) Single nucleotide variants and indels. Color legend of the variations represented, including frame-
shift indel, inframe indel missense, and nonsense. Vertical lines indicate gene names; horizontal lines indicate cases with germline mutations. (B) Copy 
number variations and fusions. Color legend of the variations represented, including amplification, fusion. Vertical lines indicate gene names; horizontal 
lines indicate cases with germline mutations. 
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treated with biomarker-driven therapy, and two were enrolled 
in biomarker matched clinical trials. BRCA1/2 mutations (n=5) 
were treated with poly ADP ribose polymerase (PARP) inhibi-
tor; a MLH1 mutation with high microsatellite instability (n=1) 
was treated with a programmed cell death-1 (PD-1) inhibitor 
(ClinicalTrials.Gov Identifier: NCT02628067), and a PIK3CA 
mutation (n=1) was treated with an AKT inhibitor (ClinicalTri-
als.Gov Identifier: NCT03017521).
Outcomes of matched therapy patients 
A total of 7 patients were treated with a targeted agent, and the 
median value of prior lines of chemotherapy was 2 (range, 2–4). 
Of the 7 patients, five received PARP inhibitor therapy, one re-
ceived PD-1 inhibitor, and one received AKT inhibitor therapy. 
Among patients who were treated with PARP inhibitor, four 
were treated with a PARP inhibitor for maintenance therapy, 
and one was treated with a PARP inhibitor as a 4th-line mono-
therapy. Among patients who underwent maintenance therapy 
with a PARP inhibitor, three were on follow-up without recur-
rence for more than 5 months; one experienced disease pro-
gression at 7 months after initiation of maintenance therapy. 
One patient treated with a PARP inhibitor as a 4th-line mono-
therapy had stable disease at the time of the analysis and had 
been undergoing treatment for 7 months. A patient treated with 
a PD-1 inhibitor experienced disease progression at 5 months 
after initiation of therapy. One patient treated with an AKT in-
hibitor had stable disease and had been undergoing treatment 
for 2 months.
Clinical impact
Clinically meaningful results are shown in Fig. 4. Clinically sig-
nificant alterations were found in 57 (67.9%) patients. Of these 
57, seven (8.3%) had matched targeted therapies, 53 (63.0%) had 
potentially actionable alterations, and eight (9.5%) and their at-
risk family members without potentially actionable alterations 
received genetic counseling. Currently, the patients with po-
tentially actionable alterations are currently either undergoing 
standard treatment or are in a state in which no disease is evi-
Fig. 2. Mutation, copy number variation profiling. (C) Homologous recombination repair (HRR)-related genes and The Cancer Genome Atlas druggable 
genes. Color legend of the variations represented, including single nucleotide variants, indel, and copy number variations. Vertical lines indicate gene 
names; horizontal lines indicate cases with germline mutations. (D) Number of mutations with six functional and targetable pathways. Vertical lines indi-
cate the number of cases with mutations; horizontal lines indicate specific genes grouped according to pathways.
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dent after treatment but remain candidates for matched ther-
apy if there is a subsequent disease recurrence or progression. 
Several patients had multiple actionable alterations. These pa-
tients received matched therapy but had other alterations that 
may later make them potential candidates for matched thera-
py. Patients with actionable alterations that could make them 
future potential candidates for matched therapy are shown in 
Table 2. 
DISCUSSION
In this study, we evaluated the clinical utility of NGS and iden-
tified clinically significant information beyond actionable alter-
ations in ovarian cancer patients. In our review of NGS results 
for the 84 ovarian cancer patients in our institution, we found 
that 57 (67.9%) of them had one or more actionable alterations 
other than TP53 and that 16 (28.6%) of them had a mutation in 
HRR-related genes. Fifty-two (61.9%) patients had clinically sig-
nificant alterations, seven (8.3%) were treated with matched 
targeted therapies, 48 (57.1%) had potentially actionable al-
terations, and eight (9.5%) received genetic counseling. In our 
study, 12 (14.3%) had germline BRCA1/2 mutations, and 50 
(59.5%) had no germline BRCA1/2 mutation. In addition, the 
distribution of patients with somatic BRCA mutations at each 
time point of NGS were 8/47 (17.0%) in the chemo-naive group 
(pre-NAC, PDS) and 3/37 (8.1%) in the post chemotherapy group 
(IDS, relapse). Incorporation of NGS into standard clinical prac-
tice could provide a complementary tool with which to identi-
fy patients who might benefit from targeted therapies and ge-
netic counseling. 
NGS has been used in several studies to identify the action-
able mutations of specific cancers and the clinical impact there-
of.11,12 Oberg, et al.11 showed the feasibility of incorporating NGS 
into pediatric hematology-oncology. They found it was clinically 
significant in 66% of all cases in which it was used. Its benefits 
included avoidance of inappropriate treatments, confirmation 
of definitive diagnoses, and identification of pharmacogenom-
ics modifiers. Heong, et al.12 described the feasibility of a mo-
lecular screening program in Asian cancer patients. Eighty-two 
percent of all patients had at least one reportable genomic al-
teration. Eight percent of the patients with reportable altera-
tions were treated with matched therapies based on their spe-
cific molecular alteration. Nine of these patients (45%; 95% CI, 
23.1–68.5%) showed a clinical benefit, including three partial 
responses and six with stable disease. However, in the SHIVA 
Ovarian cancer patients treated in our institution between 
March 1, 2017, and July 31, 2018 (n=227)
No NGS analysis
(n=143)
Matched therapy (n=7)
-  BRCA 1/2 mutation: 
Olaparib (n=5)
-  MLH1 mutation:
Pembrolizumab (n=1)
-  PIK3CA mutation: 
AKT inhibitor (n=1)
Clinical trials enrolled
- Bortezomib/Caelyx* (n=2)
- Prexasertib† (n=1)
Standard chemotherapy
(n=24)
Not-matched  
  (n=49)
-  Standard 
chemotherapy
IHC matched  
  (n=1)
-  PD-L1 (+): 
Avelumab
NGS analysis (n=84)
≥1 actionable alteration
except TP53 (n=57)
No actionable alteration
(n=27)
Fig. 3. CONSORT diagram. *ClinicalTrials. Gov Identifier: NCT03509246; †ClinicalTrials.Gov Identifier: NCT03414047. NGS, next generation sequencing; IHC, 
immunohistochemistry; PD-L1, programmed cell death-ligand 1. 
Clinically impactful
Genetic counseling: 8 (9.5%)
No clinical impact
Potential change: 53 (63.0%)
Target therapy: 7 (8.3%)
27 (32.1%)47 3
3 2
2
Fig. 4. Clinical impact of next generation sequencing panel.    
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trial,13 treatment with matched targeted agents based on a pa-
tient’s actionable molecular alterations did not improve pro-
gression-free survival in heavily pretreated cancer patients, 
compared with their physicians’ treatment choices. However, 
no studies have been conducted to assess the clinical impact, 
if any, of using NGS to identify actionable mutations in ovarian 
cancer patients.
In our study, 61.9% of all patients were identified as poten-
tial candidates for targeted therapy. This is comparable with 
other studies and may be the rationale for performing compre-
hensive genomic analysis in ovarian cancer patients. Despite 
our findings, only 8.3% of patients received targeted therapy. 
Even after their detection, matching susceptible mutations with 
specific efficacious treatment agents is especially difficult with 
ovarian cancer patients. Ovarian cancers have heterogeneous 
cell populations, an extremely complex etiology, and any num-
ber of mutations can occur as the cancer develops.14 As a fur-
ther complication, health insurers are not obligated to cover 
the off-label use of expensive drugs.
Nevertheless, the incorporation of NGS into the treatment of 
ovarian cancer may have a significant clinical impact, includ-
ing success in finding potential candidates for future targeted 
therapies and genetic counseling. In our study, 57.1% of all pa-
tients were potential candidates for future targeted therapy, and 
9.5% of all patients received genetic counseling for the patient 
and their at-risk family members. In addition, the proportion 
of somatic BRCA mutations varied according to the time point 
of NGS analysis. Although the number of patients was small, 
the difference in the proportion of patients with somatic BRCA 
mutations in the two groups may be due to the effect of BRCA 
reversion by platinum-based chemotherapy. Reversion muta-
tions in BRCA1/2 have been reported in ovarian cancer as a 
mechanism of acquired resistance to platinum-based chemo-
therapies and PARP inhibitors.15,16 Based on these results, fur-
ther studies are needed to analyze the genetic alterations in se-
rial samples of chemo-naïve and post-chemotherapy patients.
Our study has some limitations. There are still cost-effective 
issues with NGS that can limit clinical testing and prevent or 
delay the initiation of targeted therapies, and failures, such as 
insufficient collection of tissues or improper sequencing, can 
lead to significantly increased turnaround times. In addition, 
our follow-up period on patients was too short to demonstrate 
definitively that matched targeted therapies based on the re-
sults of NGS yield better outcomes than empiric treatment 
choices. 
 NGS may help guide immediate and future treatment op-
tions for patients with ovarian cancer. Implementation of NGS 
served as a complementary tool to identify patients who may 
benefit from targeted therapies and genetic counseling. Fur-
ther large-scale studies are needed to investigate the overall 
clinical utility and feasibility of NGS in ovarian cancer. 
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